Psychedelic Therapeutics Market- By Origin of Substance
Psychedelic Therapeutics Market- By Type of Psychedelic Substance
Psychedelic Therapeutics Market- By Target Disease Indications
Psychedelic Therapeutics Market- By Route of Administration
Global Psychedelic Therapeutics Market Revenue (US$ Mn) Based on Region
Europe Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
North America Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
Latin America Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Psychedelic Therapeutics Market Snapshot
Chapter 4. Global Psychedelic Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Origin of Substance Estimates & Trend Analysis
5.1. by Origin of Substance & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Origin of Substance:
5.2.1. Natural
5.2.2. Synthetic
Chapter 6. Market Segmentation 2: by Type of Psychedelic Substance Estimates & Trend Analysis
6.1. by Type of Psychedelic Substance & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Psychedelic Substance:
6.2.1. Gamma-hydroxybutyrate
6.2.2. Ketamine
6.2.3. MDMA
6.2.4. Psilocybin
Chapter 7. Market Segmentation 3: by Target Disease Indications Estimates & Trend Analysis
7.1. by Target Disease Indications & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Target Disease Indications:
7.2.1. Depression and Anxiety Disorders
7.2.2. Pain Disorders
7.2.3. Sleep Related Disorders
7.2.4. Trauma
Chapter 8. Market Segmentation 4: by Route of Administration Estimates & Trend Analysis
8.1. by Route of Administration& Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Route of Administration:
8.2.1. Oral
8.2.2. Intravenous
8.2.3. Intranasal
8.2.4. Sublingual
Chapter 9. Psychedelic Therapeutics Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.1.2. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.1.3. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.1.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.1.5. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.2. Europe
9.2.1. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.2.2. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.2.3. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.2.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.2.5. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.3.2. Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.3.3. Asia-Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.3.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.3.5. Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.4. Latin America
9.4.1. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.4.2. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.4.3. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034 North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.4.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.4.5. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.5.2. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.5.3. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.5.4. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.5.5. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Celon Pharma S.A.
9.2.2. MAPS Public Benefit
9.2.3. MindMed
9.2.4. Janssen Pharmaceuticals
9.2.5. iX Biopharma Ltd
9.2.6. Jazz Pharmaceutical
9.2.7. Avadel
9.2.8. Pharmaceuticals plc
9.2.9. NeuroRx, Inc.
9.2.10. Douglas Pharmaceuticals Limited
9.2.11. The Emmes
9.2.12. Company, LLC
9.2.13. CaaMTech
9.2.14. COMPASS Pathways plc
9.2.15. Eleusis Benefit Corporation
9.2.16. AWAKN Life Sciences Inc
9.2.17. Psilera Bioscience
9.2.18. Braxia Scientific Corp.
9.2.19. Mindset Pharma
9.2.20. BetterLife Pharma
9.2.21. Cybin
9.2.22. CB Therapeutics
9.2.23. Numinus Wellness
9.2.24. Mydecine Innovations Group
9.2.25. Optimi Health
9.2.26. PharmaTher
9.2.27. Field Trip Health
9.2.28. ATAI Life Sciences
9.2.29. GH Research
9.2.30. Seelos Therapeutics
9.2.31. Small Pharma
9.2.32. Bright Minds Biosciences
9.2.33. Incannex Health
9.2.34. PsyBio Therapeutics
9.2.35. Universal Ibogaine
9.2.36. Levitee Labs
9.2.37. Mind Cure Health
9.2.38. Novamind
9.2.39. Clearmind Medicine
9.2.40. MYND Life Science
9.2.41. Wesana Health
9.2.42. Psyched Wellness
9.2.43. HAVN Life Sciences
9.2.44. Tryp Therapeutics
9.2.45. Psyence Group
9.2.46. Silo Pharma
9.2.47. Core One Labs
9.2.48. M2Bio Sciences
9.2.49. Neonmind Biosciences
9.2.50. Delic Corp
9.2.51. Nova Mentis Life Science
9.2.52. Beckley Psytech
9.2.53. Delix Therapeutics
9.2.54. Diamond Therapeutics
9.2.55. Tactogen
9.2.56. Psygen Labs Inc.
9.2.57. Bexson Biomedical
9.2.58. Eleusis Biotech
9.2.59. Psilera Biosceince
9.2.60. Octarine Bio
9.2.61. Heading Health
9.2.62. MAPS Public Benefit Corporation (PBC)
9.2.63. Aphrodite Health
9.2.64. Terran Biosciences
9.2.65. Mycrodose Therapeutics
9.2.66. Reset Pharma
9.2.67. Clerkenwell Health
9.2.68. Alvarius Pharmaceuticals
9.2.69. Ceruvia Lifesciences
9.2.70. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.